×
0 0.00184501845018453 0.00184501845018453 0.00428044280442803 -0.011070110701107 -0.033210332103321 -0.018450184501845 -0.011070110701107
Stockreport

Iovance Bio's mid-stage study of LN-144 in melanoma underway [Seeking Alpha]

IOVANCE BIOTHERAPEUTICS (IOVA)  More Company Research Source: Seeking Alpha
Last iovance biotherapeutics earnings: 5/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: iovance.com
PDF Iovance Bio's mid-stage study of LN-144 in melanoma underwayThe first patient has beendosed in a Phase 2 clinical trial,C-144-01, assessing Iovance Biotherapeutics' (IOVA-3.2%) lead candidate LN-144 (lifileucel) in metastatic melanoma patients. The primary endpoint of the 85-subject study is objective response rate (ORR) at month 6.According to ClinicalTrials.gov, the estimated primary completion date is March 2019.LN-144 is a cell therapy, specifically, autologous tumor infiltrating lymphocytes extracted from the patient, expanded in the laboratory and then reinfused where they attack and kill cancer cells.Click to subscribe to real-time analytics on IOVANow read:Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up » [Read more]

IMPACT SNAPSHOT EVENT TIME: IOVA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS